Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries

Cardiovascular Research

Volumn 56, Issue 3, 2002, Pages 454-463

  Yin, Xinhua ^a,c   Yutani, Chikao ^a   Ikeda, Yoshihiko ^a   Enjyoji, Keiichi ^a   Ishibashi Ueda, Hatsue ^a   Yasuda, Satoshi ^a   Tsukamoto, Yoshitane ^a   Nonogi, Hiroshi ^a   Kaneda, Yasufumi ^b   Kato, Hisao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angioplasty; Atherosclerosis; Gene therapy; Remodeling; Restenosis

Indexed keywords

LIPOSOME; RNA; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOGRAPHY; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CATHETER; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; EXPRESSION VECTOR; FOLLOW UP; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HISTOPATHOLOGY; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RABBIT; RESTENOSIS; SAFETY;

ANGIOPLASTY, BALLOON; ANIMALS; ARTERIOSCLEROSIS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; ILIAC ARTERY; LIPOPROTEINS; LIPOSOMES; MALE; RABBITS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0036890148     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00595-3     Document Type: Article

References (48)

1. Libby P., Tanaka H. The molecular bases of restenosis. Prog. Cadiovasc. Dis. 40:(2):1997;97-106.
2. Faxon D.P., Coats W., Currier J. Remodeling of the coronary artery after vascular injury. Prog. Cadiovasc. Dis. 40:(2):1997;129-140.
3. Yutani C., Imakita M., Ishibashi-Ueda H., et al. Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol Int. 49:1999;273-290.
4. Taubman M.B., Giesen P.L.A., Schecter A.D., Nemerson Y. Regulation of the procoagulant response to arterial injury. Thromb Haemost. 82:(2):1999;801-805.
5. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 30:1991;10363-10370.
6. Taubman M.B., Fallon J.T., Schecter A.D., et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 78:1997;200-204.
7. Speidel C.M., Eisenberg P.R., Ruf W., Edgington T.S., Abendschein D.R. Tissue factor mediated prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation. 92:1995;3323-3330.
8. Marmur J.D., Rossikhina M., Guha A., et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin. Invest. 91:1993;2253-2259.
9. Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 86:1989;2839-2843.
10. McNamara C.A., Sarembock I.J., Bachhuber B.G., et al. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost. 22:1996;139-144.
11. Gasic G.P., Arenas C.P., Gasic T.B., Gasic G.J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cell. Proc Natl Acad Sci USA. 89:1992;2317-2320.
12. Hasenstab D., Lea H., Hart C.E., Lok S., Clowes A.W. Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis. Circulation. 101:2000;2651-2657.
13. Girard T.J., Warren L.A., Novotny W.F., et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 338:(6):1989;518-520.
14. Camici M., Sagripanti A. Tissue factor pathway inhibitor. Minerva Med. 90:1999;25-32.
15. Zoldhelyi P., McNatt J., Shelat H.S., et al. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation. 101:2000;289-295.
16. Oltrona L., Speidel C.M., Recchia D., et al. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation. 96:1997;646-652.
17. Jeffrey M., Isner M.D. Vascular remodeling. Circulation. 89:1994;2937-2941.
18. Kakuta T., Currier J.W., Haudenschild C.C., Ryan T., Faxon D.P. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 89:1994;2809-2815.
19. Kibbe M.R., Billiar T.R., Tzeng E. Gene therapy for restenosis. Circ Res. 86:2000;829-833.
20. O'Brien T., Simari R.D. Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution. Mayo Clin Proc. 75:2000;831-834.
21. O'Brien T. Adenoviral vectors and gene transfer to the blood vessel wall. Arteroscler Thromb Vasc Biol. 20:2000;1414-1416.
22. Kaneda Y., Iwai K., Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 243:1989;375-378.
23. Kaneda Y., Saeki Y., Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol. Med. Today. 5:1999;298-303.
24. Kaneda Y. Fusigenic sendai-virus liposomes: a novel hybrid type liposome for gene therapy. Biogenic Amines. 14:(5):1998;553-572.
25. Saeki Y., Matsumoto N., Nakano Y., et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai Virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 8:1997;2133-2141.
26. Tsuboniwa N., Morishita R., Hirano T., et al. Safety evaluation of hemagglutinating virus of Japan-artificial viral envelope liposomes in nonhuman primates. Hum. Gene Ther. 12:2001;469-487.
27. Yonemitsu Y., Kaneda Y., Morishita R., et al. Characterization of in vivo gene transfer into the arterial wall mediated by the sendai virus (Hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 75:(3):1996;313-323.
28. Yano T., Kawano H., Mochizuki H., et al. Atherosclerotic plaques composed of a large core of foam cells covered with thin fibrous caps in twice-injured carotid arterial specimens obtained from high cholesterol diet-fed rabbits. J Atheroscler Thromb. 7:(2):2000;83-90.
29. Stadius M.L., Collins C., Kernoff R., Calif S. Local infusion balloon angioplasty to obviate restenosis compared with conventional balloon angioplasty in an experimental model of atherosclerosis. Am Heart J. 126:(1):1993;47-56.
30. Sarembock I.J., Gertz S.D., Gimple L.W., et al. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 84:(1):1991;232-243.
31. Abumiya T., Enjyoji K., Kokawa T., Kamikubo Y., Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem. 118:1995;178-182.
32. 243, of the third Kunitz domain is a heparin-binding site. Biochemistry. 34:1995;5725-5735.
33. Caplice N.M., Mueske C.S., Kleppe L.S., et al. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res. 83:1998;1264-1270.
34. Caplice N.M., Mueske C.S., Kleppe L.S., Broze G.J., Simari R.D. Expression and regulation of tissue factor pathway inhibitor in arteries and vascular smooth muscle cells. Circulation. 96:(suppl. I):1997;I-663.
35. Caplice N.M., Mueske C.S., Kleppe L.S., Simari R.D. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation. 98:1998;1051-1057.
36. Drew A.F., Davenport P., Apostolopoulos J., Tipping P.G. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest. 77:(4):1997;291-298.
37. Kamikubo Y., Nakahara Y., Takemoto S., et al. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 407:1997;116-120.
38. Sato Y., Asada Y., Marutsuka K., et al. Tissue factor pathway inhibitor aortic smooth muscle cell migration induced by tissue factor/factor VII complex. Thromb Haemost. 78:1997;1138-1141.
39. Ismail A., Khosravi H., Olson H. The role of infection in atherosclerosis and coronary artery disease: a new therapeutic target. Heart Dis. 1:(4):1999;189.
40. Penn M.S., Topol E.J. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res. 89:2001;1-2.
41. Nakamura Y., Nakamura K., Ohta K., et al. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. Basic Res Cardiol. 97:(3):2002;198-205.
42. de Smet B.J.G.L., Pasterkamp G., van der Helm Y.J., Borst C., Post M.J. The relation between de novo atherosclerosis remodeling and angioplasty-induced remodeling in an atherosclerotic Yucatan micropig model. Arterioscler Thromb Vasc Biol. 18:1998;702-707.
43. Singh R., Pan S., Mueske C.S., et al. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res. 89:2001;71-76.
44. Nishida T., Ueno H., Atsuchi N., et al. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res. 84:1999;1446-1452.
45. Atsuchi N., Nishida T., Marutsuka K., et al. Combination of brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation. 103:2001;570-575.
46. Zoldhelyi P., Chen Z.Q., Shelat H.S., McNatt J.M., Willerson J.T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA. 98:(7):2001;4078-4083.
47. Horie H., Takahashi M., Izumi M., et al. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Circulation. 96:(1):1997;166-173.
48. Tenda K., Saikawa T., Maeda T., et al. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J. 57:(8):1993;789-795.